Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer
Author(s) -
Edvin Murrja,
Hande Turna,
Mehmet Akif Öztürk,
Ahmet Cinkaya,
Tülin Öztürk
Publication year - 2014
Publication title -
medical science and discovery
Language(s) - English
Resource type - Journals
ISSN - 2148-6832
DOI - 10.17546/msd.82203
Subject(s) - medicine , pathological , triple negative breast cancer , breast cancer , oncology , aldehyde dehydrogenase , stage (stratigraphy) , cancer , triple negative , chemotherapy , distributed file system , lactate dehydrogenase , pathology , gene , enzyme , paleontology , biochemistry , chemistry , computer security , biology , computer science
Objective: Understanding of other biological characteristics of Triple-negative breast cancer, the development of new therapeutical approaches and identification of new markers is necessary due to the lack of biological markers like ER, PR and HER2. The purpose of this study was to investigate the prognostic effect of the expression of aldehyde dehydrogenase-1 (ALDH1) in TNBC and its relationship with the clinico-pathological features Methods: In this study 87 patient files were searched for clinico-pathological data obtained from the files and paraffin blocks. The prognostic value of these clinical data and ALDH1 positivity were evaluated by determining disease-free survival. Results: TNM stage I vs III (p=0.03), vascular invasion (p=0.05), chemotherapy indication (p=0.02) were significantly associated with DFS. Multivariable analyses didn't demonstrate any statistically significant relationship between ALDH1 (p=0.61) and DFS. Conclusions: We didn\'t find any statistically significant relationship between ALDH1 positivity and DFS. There was no correlation between ALDH1 expression and tumor\'s pathological features .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom